Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies
- PMID: 33315067
- PMCID: PMC7752053
- DOI: 10.1042/ETLS20190154
Approaches to treating tuberculosis by encapsulating metal ions and anti-mycobacterial drugs utilizing nano- and microparticle technologies
Abstract
Tuberculosis (TB) is caused by a bacterial infection that affects a number of human organs, primarily the lungs, but also the liver, spleen, and spine, causing key symptoms of fever, fatigue, and persistent cough, and if not treated properly, can be fatal. Every year, 10 million individuals become ill with active TB resulting with a mortality approximating 1.5 million. Current treatment guidelines recommend oral administration of a combination of first-line anti-TB drugs for at least 6 months. While efficacious under optimum conditions, 'Directly Observed Therapy Short-course' (DOTS) is not without problems. The long treatment time and poor pharmacokinetics, alongside drug side effects lead to poor patient compliance and has accelerated the emergence of multi-drug resistant (MDR) organisms. All this, combined with the limited number of newly discovered TB drugs to treat MDR-TB and shorten standard therapy time, has highlighted the need for new targeted drug delivery systems. In this respect, there has been recent focus on micro- and nano-particle technologies to prepare organic or/and metal particles loaded with TB drugs to enhance their efficacy by targeted delivery via the inhaled route. In this review, we provide a brief overview of the current epidemiology of TB, and risk factors for progression of latent stage tuberculosis (LTBI) to the active TB. We identify current TB treatment regimens, newly discovered TB drugs, and identify studies that have used micro- or nano-particles technologies to design a reliable inhalation drug delivery system to treat TB more effectively.
Keywords: Mycobacterium tuberculosis; antibiotics; inhalation; nanoparticles.
© 2020 The Author(s).
Conflict of interest statement
The authors declare that there are no competing interests associated with the manuscript.
Figures
Similar articles
-
[Development of antituberculous drugs: current status and future prospects].Kekkaku. 2006 Dec;81(12):753-74. Kekkaku. 2006. PMID: 17240921 Review. Japanese.
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
[Recent progress in mycobacteriology].Kekkaku. 2007 Oct;82(10):783-99. Kekkaku. 2007. PMID: 18018602 Japanese.
-
API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.J Assoc Physicians India. 2006 Mar;54:219-34. J Assoc Physicians India. 2006. PMID: 16800350
-
[Prospects for development of new antituberculous drugs].Kekkaku. 2002 Aug;77(8):573-84. Kekkaku. 2002. PMID: 12235850 Japanese.
Cited by
-
The Biological and Clinical Aspects of a Latent Tuberculosis Infection.Trop Med Infect Dis. 2022 Mar 8;7(3):48. doi: 10.3390/tropicalmed7030048. Trop Med Infect Dis. 2022. PMID: 35324595 Free PMC article. Review.
-
Recent Advances in Nanotechnology-Based Strategies for Bone Tuberculosis Management.Pharmaceuticals (Basel). 2024 Jan 29;17(2):170. doi: 10.3390/ph17020170. Pharmaceuticals (Basel). 2024. PMID: 38399384 Free PMC article. Review.
-
Protective Effect of Rifampicin Loaded by HPMA-PLA Nanopolymer on Macrophages Infected with Mycobacterium Tuberculosis.Comput Math Methods Med. 2022 Jan 4;2022:5784283. doi: 10.1155/2022/5784283. eCollection 2022. Comput Math Methods Med. 2022. Retraction in: Comput Math Methods Med. 2023 Jun 28;2023:9763816. doi: 10.1155/2023/9763816. PMID: 35027942 Free PMC article. Retracted.
-
MicroRNA‑502‑3p promotes Mycobacterium tuberculosis survival in macrophages by modulating the inflammatory response by targeting ROCK1.Mol Med Rep. 2021 Nov;24(5):753. doi: 10.3892/mmr.2021.12393. Epub 2021 Sep 3. Mol Med Rep. 2021. PMID: 34476503 Free PMC article.
-
Iron, Copper, and Zinc Homeostasis in the Battle between Macrophage and Mycobacterium Tuberculosis.Curr Med Chem. 2025;32(16):3155-3168. doi: 10.2174/0109298673283407231225140659. Curr Med Chem. 2025. PMID: 38231073 Review.
References
-
- WHO. (2020) Tuberculosis, World Health Organization
-
- CDC, Tuberculosis: General Information, C.f.D.C.a. Prevention. (2011) National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical